Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction

Current Opinion in HIV and AIDS

Volumn 2, Issue 4, 2007, Pages 253-260

  Côté, Hélène C F ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Mitochondrial dysfunction; mtDNA depletion; mtDNA mutation; Nucleoside reverse transcriptase inhibitor related toxicity

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTOCHROME C OXIDASE; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; LINEZOLID; MITOCHONDRIAL DNA; MITOCHONDRIAL RNA; POLYRIBONUCLEOTIDE NUCLEOTIDYLTRANSFERASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STATIN; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ANEMIA; CARDIOMYOPATHY; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME INHIBITION; FATTY LIVER; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC PREDISPOSITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; KIDNEY FAILURE; LIPOATROPHY; LIVER FAILURE; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL DNA REPLICATION; MITOCHONDRIAL TOXICITY; MYOPATHY; NEUTROPENIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RNA TRANSCRIPTION; VIRUS TRANSMISSION;

EID: 34250644231     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3281df3410     Document Type: Review

References (79)

1. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003; 2:812-822.
2. Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 2006; 47:1-7.
3. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811-820.
4. Miro O, Lopez S, Martinez E, et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 2004; 39:710-716.
5. Haugaard SB, Andersen O, Pedersen SB, et al. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. J Med Virol 2005; 77:29-38.
6. Casula M, Bosboom-Dobbelaer I, Smolders K, et al. Infection with HIV-1 induces a decrease in mtDNA. J Infect Dis 2005; 191:1468-1471.
7. Jacotot E, Ravagnan L, Loeffler M, et al. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 2000; 191:33-46.
8. Lewis W, Kohler JJ, Hosseini SH, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 2006; 20:675-684.
9. Samuels DC. Mitochondrial AZT metabolism. IUBMB Life 2006; 58:403-408.
10. Hance N, Ekstrand MI, Trifunovic A. Mitochondrial DNA polymerase gamma is essential for mammalian embryogenesis. Hum Mol Genet 2005; 14:1775-1783.
11. Cote HC, Magil AB, Harris M, et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 2006; 11:79-86.
12. Lopez S, Negredo E, Garrabou G, et al. Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. AIDS Res Hum Retroviruses 2006; 22:33-39.
13. Vidal F, Domingo JC, Guallar J, et al. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 2006; 50:3824-3832.
14. Lynx MD, Bentley AT, McKee EE. 3′-Azido-3′-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: a possible mechanism of AZT hepatotoxicity. Biochem Pharmacol 2006; 71:1342-1348. An animal study showing that in rat liver mitochondria, zidovudine is phosphorylated to zidovudine monophosphate, but no further phosphorylated forms were detected. In addition, zidovudine inhibited the production of thymidine triphosphate.
15. Rylova SN, Albertioni F, Flygh G, Eriksson S. Activity profiles of deoxynucleoside kinases and 5′-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs. Biochem Pharmacol 2005; 69:951-960.
16. Susan-Resiga D, Bentley AT, Lynx MD, et al. Zidovudine inhibits thymidine phosphorylation in the isolated perfused rat heart. Antimicrob Agents Chemother 2007; 51:1142-1149.
17. Skulachev VP. Bioenergetic aspects of apoptosis, necrosis and mitoptosis. Apoptosis 2006; 11:473-485. A most interesting and original point of view on the various mitochondria-related phenomena.
18. Lyamzaev KG, Pletjushkina OY, Saprunova VB, et al. Selective elimination of mitochondria from living cells induced by inhibitors of bioenergetic functions. Biochem Soc Trans 2004; 32:1070-1071.
19. Seidel-Rogol BL, Shadel GS. Modulation of mitochondrial transcription in response to mtDNA depletion and repletion in HeLa cells. Nucl Acids Res 2002; 30:1929-1934.
20. Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191:1686-1696.
21. Cote H, Forbes J, Alimenti A, et al. Decreased blood mitochondrial (mt) gene expression (CCOI/beta-actin) in the absence of mitochondrial DNA (mtDNA) depletion in 1-3 days old neonates exposed to highly active antiretroviral therapy (HAART) during pregnancy. In: XVIth International AIDS Conference. Toronto, Canada 13-18 August 2006; Abstract MOPE0241.
22. Galluzzi L, Pinti M, Troiano L, et al. Changes in mitochondrial RNA production in cells treated with nucleoside analogues. Antivir Ther 2005; 10:191-195.
23. Casula M, Weverling GJ, Wit FW, et al. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. J Infect Dis 2005; 192:1794-1800.
24. Amiott EA, Jaehning JA. Mitochondrial transcription is regulated via an ATP 'sensing' mechanism that couples RNA abundance to respiration. Mol Cell 2006; 22:329-338.
25. Amiott EA, Jaehning JA. Sensitivity of the yeast mitochondrial RNA polymerase to +1 and +2 initiating nucleotides. J Biol Chem 2006; 281:34982-34988. This elegant study in a yeast system proposes that initiating nucleotides, particularly the +2 nucleoside triphosphates, are required at high concentrations to drive mitochondrial promoter opening or to stabilize a productive open complex.
26. Song S, Pursell ZF, Copeland WC, et al. DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity. Proc Natl Acad Sci U S A 2005; 102:4990-4995.
27. Olivero OA, Parikka R, Poirier MC, Vahakangas K. 3′-Azido-3′- deoxythymidine (AZT) transplacental perfusion kinetics and DNA incorporation in normal human placentas perfused with AZT. Mutat Res 1999; 428:41-47.
28. Smigrodzki RM, Khan SM. Mitochondrial microheteroplasmy and a theory of aging and age-related disease. Rejuv Res 2005; 8:172-198.
29. Santoro A, Salvioli S, Raule N, et al. Mitochondrial DNA involvement in human longevity. Biochim Biophys Acta 2006; 1757:1388-1399.
30. Trifunovic A. Mitochondrial DNA and ageing. Biochim Biophys Acta 2006; 1757:611-617.
31. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell 2006; 125:1241-1252. A modern look at this age-old organelle, its functions and dysfunctions. It also presents the new 'look' of the mitochondria, not as a discrete organelle as seen in electron microscopy photographs, but rather as a constant flux of fusing and dividing mitochondria.
32. Trifunovic A, Wredenberg A, Falkenberg M, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004; 429:417-423.
33. Kujoth GC, Hiona A, Pugh TD, et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005; 309:481-484.
34. Trifunovic A, Hansson A, Wredenberg A, et al. Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production. Proc Natl Acad Sci U S A 2005; 102:17993-17998.
35. Martin AM, Hammond E, Nolan D, et al. Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am J Hum Genet 2003; 72:549-560.
36. McComsey G, Bai RK, Maa JF, et al. Extensive investigations of mitochondrial DNA genome in treated HIV-infected subjects: beyond mitochondrial DNA depletion. J Acquir Immune Defic Syndr 2005; 39:181-188.
37. Kamemoto LE, Shiramizu B, Gerschenson M. HIV-associated mitochondrial toxicity in pregnancy. Mitochondrion 2004; 4:153-162.
38. Poirier MC, Olivero OA, Walker DM, Walker VE. Perinatal genotoxicity and carcinogenicity of antiretroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004; 199:151-161.
39. Divi RL, Leonard SL, Kuo MM, et al. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ Mol Mutagen 2006; 48:201-209. This study shows that mitochondria in umbilical cord endothelial cells from NRTI-exposed monkey and human infants both showed substantial abnormal pathology by electron microscopy.
40. Chan SS, Santos JH, Meyer JN, et al. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. Environ Mol Mutagen 2006; 48:190-200. This study in mice of the most commonly used NRTI combination in pregnancy suggests that perinatal exposure to zidovudine/lamivudine produces greater heart mtDNA damage than either agent individually, and that female mice are more sensitive than males to zidovudine/lamivudine-induced mtDNA damage.
41. Venhoff N, Walker UA. Mitochondrial disease in the offspring as a result of antiretroviral therapy. Expert Opin Drug Safety 2006; 5:373-381.
42. Blanche S, Tardieu M, Benhammou V, et al. Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS 2006; 20:1685-1690. This opinion piece raises and reviews the issues surrounding mitochondrial dysfunction in children exposed perinatally to NRTIs, and addresses discrepancies and controversies in the field of research.
43. Benhammou V, Tardieu M, Warszawski J, et al. Clinical mitochondrial dysfunction in uninfected children born to HIV-infected mothers following perinatal exposure to nucleoside analogues. Environ Mol Mutagen 2007; 48:173-178. This article reviews mitochondrial toxicity in HIV-uninfected children who were exposed to NRTIs in utero. It makes an important distinction between the relatively common short-term reversible symptoms of NRTI exposure such as hyperlactatemia and the rare but more serious and unexplained irreversible long-term neurological symptoms and mitochondrial dysfunction observed in the French Perinatal Cohort as well as other cohorts.
44. Brogly S, Williams P, Seage GR III, Van Dyke R. In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and 219C cohorts. J Acquir Immune Defic Syndr 2006; 41:535-536.
45. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007; 21: In press.
46. Alimenti A, Forbes JC, Oberlander TF, et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics 2006; 118:1139-1145.
47. Lund KC, Wallace KB. Direct, DNA pol-gamma-independent effects of nucleoside reverse transcriptase inhibitors on mitochondrial bioenergetics. Cardiovasc Toxicol 2004; 4:217-228.
48. Leszczyniecka M, Kang DC, Sarkar D, et al. Identification and cloning of human polynucleotide phosphorylase, hPNPase old-35, in the context of terminal differentiation and cellular senescence. Proc Natl Acad Sci U S A 2002; 99:16636-16641.
49. Chen HW, Rainey RN, Balatoni CE, et al. Mammalian polynucleotide phosphorylase is an intermembrane space RNase that maintains mitochondrial homeostasis. Mol Cell Biol 2006; 26:8475-8487.
50. Hayakawa H, Sekiguchi M. Human polynucleotide phosphorylase protein in response to oxidative stress. Biochemistry 2006; 45:6749-6755.
51. Miro O, Lopez S, Rodriguez de la Concepcion M, et al. Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine. J Acquir Immune Defic Syndr 2004; 37:1550-1555.
52. Piechota J, Szczesny R, Wolanin K, et al. Nuclear and mitochondrial genome responses in HeLa cells treated with inhibitors of mitochondrial DNA expression. Acta Biochim Pol 2006; 53:485-495. Cultured HeLa cells exposed to dideoxycytidine underwent a 10-fold decrease of the mtDNA copy number but maintained almost normal cytochrome c oxidase activity. The mtDNA depletion was compensated mostly at the RNA metabolism level in the mitochondria.
53. Miro O, Garrabou G, Lopez S, et al. Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir. Antivir Ther 2006; 11:625-630.
54. Cote HC. Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy. Antivir Ther 2005; 10 (Suppl 2):M3-M11.
55. Chiappini F, Teicher E, Saffroy R, et al. Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients. Lab Invest 2004; 84:908-914.
56. Maagaard A, Holberg-Petersen M, Kollberg G, et al. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther 2006; 11:601-608.
57. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007; In press.
58. Gerschenson M, Shiramizu B, LiButti DE, Shikuma CM. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther 2005; 10 (Suppl 2):M83-M89.
59. Garrabou G, Sanjurjo E, Miro O, et al. Noninvasive diagnosis of mitochondrial dysfunction in HAART-related hyperlactatemia. Clin Infect Dis 2006; 42:584-585.
60. Banasch M, Goetze O, Hollborn I, et al. 13C-Methionine breath test detects distinct hepatic mitochondrial dysfunction in HIV-infected patients with normal serum lactate. J Acquir Immune Defic Syndr 2005; 40:149-154.
61. Milazzo L, Piazza M, Sangaletti O, et al. [13C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity. J Antimicrob Chemother 2005; 55:84-89.
62. Walker UA, Auclair M, Lebrecht D, et al. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006; 11:25-34.
63. Banasch M, Goetze O, Knyhala K, et al. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients. AIDS 2006; 20:1554-1556.
64. Lebrecht D, Vargas-Infante YA, Setzer B, et al. Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology 2007; 45:72-79.
65. Setzer B, Schlesier M, Thomas AK, Walker UA. Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes. Antivir Ther 2005; 10:327-334.
66. Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS Clinical Trials Group study. AIDS 2005; 19:1341-1349.
67. Kallianpur AR, Hulgan T, Canter JA, et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS 2006; 20:1503-1513.
68. Rodriguez-Novoa S, Barreiro P, Jimenez-Nacher I, Soriano V. Overview of the pharmacogenetics of HIV therapy. Pharmacogenom J 2006; 6:234-245.
69. Owen A, Pirmohamed M, Khoo SH, Back DJ. Pharmacogenetics of HIV therapy. Pharmacogenet Genom 2006; 16:693-703.
70. Hulgan T, Haas DW. Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity. J Infect Dis 2006; 194:1471-1474.
71. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect Genet Evol 2007; 7:333-342.
72. Anderson PL, Lamba J, Aquilante CL, et al. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 2006; 42:441-449.
73. Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194:1481-1491.
74. Cote HC, Brumme ZL, Chan JW, et al. HIV therapy, hepatitis C virus infection, antibiotics and obesity, a mitochondria killer mix? AIDS 2006; 20:1343-1345.
75. Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med 2005; 353:2305-2306.
76. Garrabou G, Soriano A, Lopez S, et al. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother 2006; 51:926-967.
77. Paiva H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78:60-68.
78. Schick BA, Laaksonen R, Frohlich JJ, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharm Ther 2007; In press.
79. Divi RL, Haverkos KJ, Humsi JA, et al. Morphological and molecular course of mitochondrial pathology in cultured human cells exposed long-term to zidovudine. Environ Mol Mutagen 2006; 48:179-189. This revealing study is among the first to demonstrate that in the absence of significant cell death, HeLa cells chronically exposed to zidovudine initially show abnormal morphology and proliferation, concomitant with an increase in the mtDNA content per cell and upregulation of mitochondrial gene expression. After long-term exposure, widespread mitochondrial morphological damage, severe mtDNA depletion, and a substantial loss of mitochondrial membrane potential were observed.